

RESEARCH ARTICLE

# Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects

Anna Montali<sup>1</sup>, Gessica Truglio<sup>1,2</sup>, Francesco Martino<sup>3</sup>, Fabrizio Ceci<sup>2</sup>, Giampiero Ferraguti<sup>2</sup>, Ester Ciociola<sup>1</sup>, Marianna Maranghi<sup>1</sup>, Francesco Gianfagna<sup>4,5</sup>, Licia Iacoviello<sup>5</sup>, Roberto Strom<sup>2</sup>, Marco Lucarelli<sup>2,6</sup>, Marcello Arca<sup>1\*</sup>

**1** Department of Internal Medicine and Allied Sciences, Atherosclerosis Unit, Sapienza University of Rome, Rome, Italy, **2** Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy, **3** Department of Pediatrics, Sapienza University of Rome, Rome, Italy, **4** Centro Ricerche Epidemiologia e Medicina Preventiva, Università dell'Insubria, Varese, Italy, **5** Department of Epidemiology and Prevention, Laboratory of Molecular and Nutritional Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Mediterraneo, Pozzilli, Italy, **6** Pasteur Institute—Cenci Bolognetti Foundation, Sapienza University of Rome, Rome, Italy

\* These authors contributed equally to this work.

\* [marcelloarca@libero.it](mailto:marcelloarca@libero.it)



## OPEN ACCESS

**Citation:** Montali A, Truglio G, Martino F, Ceci F, Ferraguti G, Ciociola E, et al. (2015) Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects. PLoS ONE 10(4): e0120099. doi:10.1371/journal.pone.0120099

**Academic Editor:** Xuewei Zhu, Wake Forest School of Medicine, UNITED STATES

**Received:** September 30, 2014

**Accepted:** January 19, 2015

**Published:** April 21, 2015

**Copyright:** © 2015 Montali et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files. Due to ethical restrictions, the anonymized individual data are fully available upon request to the corresponding author, Dr. Arca, at the reported address.

**Funding:** The study was supported by research grants from Progetto Ateneo 2004 University of Rome La Sapienza C26A042949 and COFIN 2004065985\_004 from MIUR to M.A. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Abstract

The precursors of atherogenic dyslipidemia (AD) are not well defined. Therefore, we investigated 62 non-obese, non-diabetic AD and 221 normolipemic children. Anthropometric parameters, blood pressure and biochemical measures were obtained in index children, their parents and all available siblings. The heritability ( $h^2$ ) of anthropometric and biochemical traits was estimated by SOLAR. Rare and common variants in *APOA1* and *LPL* genes were screened by re-sequencing. Compared to normolipemic, AD children showed increased body mass index, waist circumference, plasma glucose, insulin, ApoB, HOMA-IR, hs-CRP and lower adiponectin ( $p < 0.001$  for all). Metabolic syndrome was present in 40% of AD while absent in controls. All traits (except adiponectin and hs-CRP) showed a strong familial aggregation, with plasma glucose having the highest heritability (89%). Overall, 4 *LPL* loss-of-function mutations were detected (p.Asp9Asn, p.Ser45Asn, p.Asn291Ser, p.Leu365Val) and their cumulative prevalence was higher in AD than in control children (0.073 vs. 0.026;  $P = 0.038$ ). The *LPL* p.S447\* gain-of-function mutation, resulted to be less frequent in AD than in control children (0.064 vs. 0.126;  $P = 0.082$ ). No variant in the *APOA1* gene was found. Our data indicate that AD is a rather common dyslipidemia in childhood; it associates with metabolic abnormalities typical of insulin resistant state and shows a strong familial aggregation. *LPL* variants may contribute to the development of AD phenotype.

**Competing Interests:** The authors have declared that no competing interests exist.

## Introduction

Atherogenic dyslipidemia (AD) is a highly atherogenic lipid abnormality characterized by the combination of increased plasma concentration of triglycerides (TG), reduced high-density lipoprotein cholesterol (HDL-C) and increased numbers of small, dense low-density lipoprotein (sdLDL) particles [1, 2]. AD is thought to occur mainly in adulthood due to a combination of genetic predisposition with aging and adiposity [3, 4]. Nevertheless, epidemiological observations have reported that the lipid components of AD—namely low HDL-C and high TG—may be present since childhood [5], thus providing the rationale for searching this form of dyslipidemia also at younger ages. The earlier identification of AD is justified by the fact that these lipid abnormalities in children and adolescents have been demonstrated to predict clinical manifestation of atherosclerosis in adulthood [6].

Conditions associated to AD are central obesity and insulin resistance, which are, in turn, strongly associated with a low-grade inflammation state and abnormalities in adipokines production [7]. Indeed, in adults with AD higher levels of serum insulin and C reactive protein (CRP) and lower levels of adiponectin have been also reported [8]. However, if these abnormalities are early or late biochemical markers of AD phenotype is not known. The investigation of a cohort of children could help in shedding light into this question.

Although it is well recognized that also genetic factors predispose to the development of AD, few studies have investigated the familial aggregation of components of this lipid phenotype. The only indirect estimates derives from studies in metabolic syndrome (MetS) whose components (insulin resistance, obesity, hypertension, and serum lipids) showed heritability values ranging from 20% to 80% [9]. On the other hand, a number of candidate genes have been linked to the lipoprotein abnormalities of AD. Among them, genes coding for lipoprotein lipase (*LPL*) and apolipoprotein AI (*APOAI*) appear to be particularly relevant due to their pivotal role in regulating both TG and HDL-C levels [10–12]. Though variants in these genes may predispose to AD, direct data in children are scanty.

Therefore, within a large investigation dedicated at dyslipidaemia in the youth, we designed this study aimed at describing the metabolic and genetic abnormalities associated to AD in children. As lipid abnormalities cluster within families, an additional aim of this study was to evaluate the familial aggregation of traits associated with this disorder and to estimate the contribution of rare and common genetic variants into *LPL* and *APOAI* genes to the lipid components of AD.

## Material and Methods

### Subjects' selection and classification

For this study we have considered all children (2–18 years) referred between November 2006 and January 2012 to the paediatric Lipid Clinic of our University Hospital for suspected dyslipidaemia [13]. At first visit, anthropometric (body weight, waist, hip and arm circumferences) and lipoprotein measurements were obtained in index children, their parents and all available siblings. In children, weight was measured using an electronic scale (Soehnle, Murrhardt, Germany), and the standing height was measured with the Harpenden Stadiometer (Holtain, Crymych, Great Britain). Systolic and diastolic blood pressure was measured by using a random zero sphygmomanometer (Hawksley & Sons Ltd, Lancing, UK); the mean of three measurements was used in the analysis. Body mass index (BMI) was calculated as weight/height<sup>2</sup> (kg/m<sup>2</sup>).

Children showing plasma levels of TG  $\geq 90^{\text{th}}$  and HDL-C  $\leq 10^{\text{th}}$  age and sex-specific percentiles were classified as AD [14], while those with TG  $< 75^{\text{th}}$  and HDL  $> 10^{\text{th}}$  were used as comparator. TG and HDL-C percentiles reported for Italian children and adult ( $> 20$  years)

populations were used as reference values [15, 16]. Children with clinical diagnosis of dominant familial hypercholesterolemia (ADH) were excluded. The criteria for diagnosing ADH have been previously reported [13]. Additional exclusion criteria were thyroid dysfunction, diabetes mellitus, nephrotic syndrome and liver disease as detected by standard laboratory tests. Subjects taking statins or other medications for lipoprotein disorder were also excluded from the analyses.

The presence of MetS in adults was defined according to the American Heart Association (AHA) criteria, [17]. To define MetS in children, we used the pediatric AHA definition which is based upon the AHA adult definition but uses pediatric reference standards for blood pressure (BP), waist circumference (WC), TGs and HDL-C [18, 19]. Thus, in our study central obesity was defined as a WC  $\geq$  90th percentile for age and gender; hyperTG as triglycerides  $\geq$  90th percentile for age and gender; low HDL-C as concentrations  $\leq$  10th percentile for age and gender; elevated BP as systolic or diastolic BP  $\geq$  90th percentile for age, gender, and height percentile; and impaired fasting glucose as glucose  $\geq$  100 mg/dl.

Written informed consent on behalf of enrolled children was obtained from parents and all adults gave their written consent before entering into the study. The study was approved by the Institutional Review Board and carried out in accordance with the Helsinki Declaration.

## Biochemical measurements

Blood samples were collected early in the morning after an overnight fast in EDTA-containing tubes. Plasma concentrations of lipoprotein apoproteins, blood glucose and insulin were determined as previously described [13, 20]. Insulin resistance was estimated by HOMA<sub>IR</sub> as previously described [21]. Plasma levels of high molecular weight (HMW) adiponectin levels were determined by ELISA kit (EZHMWA A-64K, Millipore, Missouri, U.S.A) according to manufacturer's instructions. Plasma high-sensitive C-reactive protein (hs-CRP) concentrations were analyzed by particle-enhanced turbidimetric immunoassay (C-Reactive Protein Latex High Sensitivity—Roche Diagnostics GmbH, D-68298 Mannheim) following manufacturer's instructions.

## Genetic analysis

Genomic DNA of 55 AD and 174 normolipemic children was obtained from peripheral blood leukocytes by either the salting-out method [22] or the QIAamp 96 Blood DNA kit (Qiagen, Hilden, Germany). The mutational search in *LPL* and *APOA1* genes was performed using the robotic system Microlab Starlet (Hamilton, Reno, USA) for the preparation of the reactions in a 96-well and the ABI PRISM 3130xl (Applied Biosystems, Foster City, USA) genetic analyzer for targeted sequencing. For the purpose of confirmation, the SNPs identified in the *LPL* gene were also investigated by using the SNaPshot assay (Life Technologies, Carlsbad, USA). Details of procedures are reported in the [S1 File](#), [S1 Table](#) and [S2 Table](#).

## Statistical analysis

Statistical analyses were performed using the SPSS package (version 18.0; SPSS Inc., Chicago, IL, USA) and STATA v.11. The data are expressed as either frequencies or means with standard deviation. The variables showing a skewed distribution were reported as median (interquartile ranges) and tested after log transformation. Student's *t*-test for unpaired data or U Mann-Whitney were used to compare continuous variables, while either Fisher's exact test or  $\chi^2$  test was used to compare categorical variables. All comparisons were adjusted for age, sex and BMI by using the generalized linear model (GLM). Pearson's correlation and linear regression coefficients were used to examine the relationship between variables.

The computer package SOLAR (Sequential Oligogenic Linkage Analysis Routines, version 4.2.7) was used for heritability analyses [23]. A maximum likelihood-based variance decomposition approach was used to estimate the proportion of the overall variability due to genetic (heritability,  $h^2$ ) and covariates effects. The significance was assessed by means of the likelihood ratio test, using the `tdist` command when residual kurtosis of the traits was  $>0.8$ , allowing a robust estimation of mean and variance of the trait. Covariates used in models included age, sex, age\*sex (sex modality was 1 or 2), entering in the final model if  $p < 0.1$ . The analysis was repeated after stratification for case and control families, maintaining statistical models and settings used for the related analysis in the whole sample. Before analysis, the distribution of variables was assessed using Shapiro-Wilk tests and variables not normally distributed were transformed when appropriate using the statistical package SAS (version 9.1.3 for Windows, Cary, NC: SAS Institute Inc.).


We also assessed the odds ratios for the presence of AD in the parents according to the status of the proband using a logistic regression model, with and without adjustment for age, age square, gender and BMI. The general estimated equation model was used to account for the correlation among siblings within a family. In addition, the probability (odds) of a child with AD to having a parent with the same lipid phenotype has been estimated by using logistic regression analysis where age, sex and BMI were included as covariates.

All statistical tests were 2-sided and a  $P < 0.05$  was set as the statistical significance level.

## Results

### Identification of AD children and families

A total number of 488 Caucasian index children were originally considered for the study. Fig 1 shows the flow diagram for classification of these children. Eighty four (17.2%) were excluded due to incomplete family data, thus leaving a study cohort of 404 children. According to the predefined criteria, 221 children (54.7%) (89 boys and 132 girls) were classified as without AD, 32 (7.9%) with autosomal dominant hypercholesterolemia (ADH) and 89 (21.9%) with either isolated low HDL-C or isolated high TG. Therefore, 62 (41 boys and 21 girls) were classified as affected by AD providing a prevalence of 15.3%. Within families with AD we examined 124 parents (62 father and 62 mothers) and 43 siblings (22 brothers and 21 sisters); within families



**Fig 1. Flow diagram for classification of children with atherogenic dyslipidemia.**

doi:10.1371/journal.pone.0120099.g001

with normolipemic children we examined 442 parents (221 father and 221 mothers) and 160 siblings (91 brothers and 69 sisters).

## Comparison of clinical and biochemical characteristics of children with and without AD

[Table 1](#) shows the comparison of clinical and biochemical characteristics between children with AD and those with normal lipids. Age and gender were not significantly different between groups, but male sex appeared to be more frequent among AD children. Although LDL-C and apoB, levels did not differ between groups, the LDL-C/Apo B ratio was lower in AD compared to controls children. As reduced LDL-C/apoB has been reported to be a good predictor of smaller LDL particles [24], this finding strongly suggests an increased prevalence of sdLDL in the AD group. Respect to controls, BMI and waist circumference were significantly greater in children with AD and these difference was present in both boys and girls (data not shown). The differences in the waist circumference remained statistically significant ( $p = 0.038$ ) also when adjusted for age and sex. Plasma levels of fasting blood glucose, insulin, HOMA-IR and hs-CRP were higher and those of HMW adiponectin were lower in children with AD compared

**Table 1. Clinical characteristics and laboratory parameters of children with and without atherogenic dyslipidemia.**

Variables	Children with atherogenic dyslipidemia (n = 62)	Children without atherogenic dyslipidemia (n = 221)
Age, (yrs)	8.2 ± 3.9	8.3 ± 3.4
Sex, Boys	41 (66%)	89 (40%)
Girls	21 (34%)	132 (60%)
BMI, (kg/m <sup>2</sup> )	21.1 ± 5.3***	18.2 ± 3.5
Systolic BP (mmHg)	106.8 ± 10.7	108.1 ± 11.2
Diastolic BP (mmHg)	68.3 ± 10.0	70.3 ± 8.9
Waist circumference (cm)	73.0 ± 16.8***	61.5 ± 9.6
<b>Plasma lipids (mg/dl)</b>		
Total cholesterol	187.3 ± 37.4	198.6 ± 38.7
HDL-C	32.9 ± 5.0***	58.8 ± 12.1
Non-HDL-C	154.4 ± 36.2***	139.8 ± 38.3
Total triglycerides	158.9 ± 83.2***	65.0 ± 19.2
LDL-C	122.5 ± 38.1	126.9 ± 37.4
ApoB	89.6 ± 27.5	82.4 ± 22.4
LDL-C/Apo B	1.39 ± 0.32**	1.65 ± 0.75
ApoAI	126.0 ± 25.6***	155.3 ± 30.9
Fasting Blood Glucose (mg/dl)	77.2 ± 11.3***	69.1 ± 11.0
Insulin (μU/ml)	11.03 ± 8.36***	6.46 ± 4.23
HOMA-IR	2.14 ± 1.64***	1.09 ± 0.8
hs-CRP (mg/dl)	0.08 (0.04–0.22) *	0.03 (0.00–0.12)
Adiponectin (μg/ml)	3.75 (2.45–6.04) ***	5.67 (3.88–7.41)
Metabolic Syndrome, n (%)	26 (42) ***	0

BMI, body mass index; BP, blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ApoB, apolipoprotein B; ApoAI, apolipoprotein AI; hs-CRP, high sensitivity C Reactive Protein; HOMA-IR, homeostasis model assessment of IR index.

hs-CRP and adiponectin values are reported as median (interquartile range)

\*  $p < 0.05$ ;

\*\*  $p < 0.01$ ;

\*\*\*  $p < 0.001$

doi:10.1371/journal.pone.0120099.t001

to controls. With the exception of those in adiponectin levels, all these differences remained statistically significant after adjustment for age, waist circumference and gender. Conversely, systolic and diastolic blood pressure did not differ significantly between groups. Twenty-six children with AD (42%) were found to have MetS compared to none among controls.

Univariate correlations between clinical and biochemical characteristics in the whole group of study children are reported in [S3 Table](#). Age was a significant determinant of FBG, insulin, HOMA-IR, BMI and waist circumference (positive) and adiponectin (negative). As expected, BMI and waist circumference were significantly correlated with indices of insulin resistance (positively) and TG and with adiponectin, HDL-C (negatively). Finally, hs-CRP showed a slight, positive correlation with plasma insulin and HOMA and negative with HDL-C and ApoAI.

## Familial aggregation of AD traits

To evaluate the familial aggregation of the AD phenotype, we first compared plasma lipids and other characteristics of parents and siblings of children with and without AD ([Table 2](#)). Parents of AD children showed significantly higher non HDL-C, TG, LDL-C, apoB and lower HDL-C and ApoAI levels compared to those of children without AD. Also, mean levels of fasting blood glucose and insulin levels were higher in parents of children with AD compared to controls, even though only the former reached a level of statistical significance. This translated in higher HOMA index in parents of children with AD, but the difference did not reach the statistical significance. Even though BMI was comparable between groups, the waist circumference was significantly greater in parents of children with dyslipidemia compared with controls indicating a tendency towards increased prevalence of visceral obesity among this group. Finally, when we compared the prevalence of MetS between groups, it was found to be almost 3 times more frequent among parents of dyslipidemic children and this difference was highly significant ( $p < 0.001$ ).

The comparison of demographic and metabolic parameters between siblings of children with and without AD showed somewhat similar differences ([Table 2](#)). In fact, brothers and sisters of affected children showed, on average, significantly higher TG and lower HDL-C and apoA1 respect to those of normolipemic children; they also presented a tendency towards higher indices of insulin resistance and visceral obesity, but the differences were not statistically significant. Nonetheless, among siblings of AD children we observed a markedly increased prevalence of MetS. To explore the extent to which AD aggregates within families further, we estimated the heritability ( $h^2$ ) of the phenotypic traits in the study groups ([S4 Table](#)). All traits, except adiponectin and hs-CRP, showed a significant genetic component, with glucose levels having the highest heritability. Plasma levels of lipoproteins as well as apolipoprotein and their ratios also showed strong genetic influence presenting  $h^2$  values ranging from 52% to 83%. The groups of children with AD showed higher heritability levels for anthropometric measures and non-HDL-C.

## Genetic analysis of *LPL* and *APOA1* genes in children with and without AD

The analysis of *APOA1* gene did not reveal any variants in both groups of children. Conversely, the screening of *LPL* led to identification of 8 exonic variants, 3 of which were synonymous. Of the 5 non-synonymous variants, 4 were missense and 1 was nonsense ([Table 3](#)). Most of them (p.Asp9Asn, p.Asn291Ser, p.Leu365Val and p.S447\*) have been previously reported [25–27], while the p.Ser45Asn variant is described here for the first time: All variants were found to be at heterozygous state. The child carrying the p.Asp9Asn resulted to be heterozygous for the



**Table 2. Clinical characteristics and laboratory parameters of parents and siblings of children with and without atherogenic dyslipidemia.**

Variables	Parents		Siblings	
	of children with atherogenic dyslipidemia(n = 124)	of children without atherogenic dyslipidemia (n = 442)	of children with atherogenic dyslipidemia (n = 43)	of children without atherogenic dyslipidemia (n = 160)
Age, (yrs)	40.0 ± 6.4	40.4 ± 5.8	11.2 ± 5.8	10.2 ± 6.2
BMI, (kg/m <sup>2</sup> )	25.5 ± 3.9	24.9 ± 4.0	21.0 ± 6.2	18.7 ± 3.9
Systolic BP (mmHg)	119.8 ± 13.0	119.2 ± 13.2	102.3 ± 12.2	104.7 ± 12.3
Diastolic BP (mmHg)	75.7 ± 8.5	76.4 ± 9.3	63.4 ± 7.2	66.4 ± 8.4
Waist circumference (cm)	93.0 ± 13.0*	88.9 ± 13.3	74.9 ± 25.1	60.3 ± 12.8
Plasma lipids (mg/dl)				
Total cholesterol	211.8 ± 46.2	205.2 ± 38.7	166.9 ± 35.9	171.1 ± 38.46
HDL-C	45.0 ± 12.3***	54.2 ± 14.5	42.4 ± 9.0**	55.0 ± 12.4
Non HDL-C	166.8 ± 47.6***	150.9 ± 41.8	124.4 ± 37.1	116.1 ± 36.0
Total triglycerides	141.5 ± 88.6***	103.7 ± 83.3	98.7 ± 63.2**	63.7 ± 23.5
LDL-C	139.0 ± 44.3*	130.1 ± 34.5	104.6 ± 34.1	103.3 ± 34.8
ApoB	94.4 ± 30.1**	86.7 ± 25.6	74.5 ± 24.9	73.5 ± 22.8
LDL-C/ApoB	1.51 ± 0.41	1.60 ± 0.56	1.49 ± 0.44	1.51 ± 0.67
ApoAI	147.8 ± 32.0***	159.1 ± 34.6	133.9 ± 27.1**	154.1 ± 31.0
Fasting Blood glucose (mg/dl)	83.2 ± 19.7***	75.9 ± 13.3	77.7 ± 12.8	72.0 ± 11.4
Insulin (μU/ml)	9.68 ± 14.0	7.93 ± 4.80	8.5 ± 7.2	6.95 ± 5.35
HOMA-IR	2.54 ± 7.31	1.55 ± 1.28	1.81 ± 1.97	1.30 ± 1.07
hs-CRP (mg/dl)	0.11 (0.04–0.29)	0.09 (0.03–0.22)	0.04 (0.01–0.11)	0.05 (0.01–0.14)
Adiponectin (μg/ml)	3.44 (2.22–4.88)	3.20 (2.09–5.46)	—	—
Metabolic Syndrome, n (%)	9 (7.2) ***	12 (2.7)	5 (11.6) **	—

BMI, body mass index; BP, blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ApoB, apolipoprotein B; ApoAI, apolipoprotein AI; hs-CRP, high sensitivity C Reactive Protein; HOMA-IR, homeostasis model assessment of IR index. hs-CRP and adiponectin values are reported as median (interquartile range)

\* P<0.05;

\*\* p<0.01;

\*\*\* p<0.001 between parents

\*\* p<0.01;

\*\*\* p<0.001 between siblings

doi:10.1371/journal.pone.0120099.t002

complex allele [c.-281T>G; c.106G>A] with the two variants in *cis* on the same allele. The segregation analysis in parents assigned this complex allele to the father. The novel *LPL* c.215 G>A (p.Ser45Asn) variation was identified in a child showing TGs of 257 and HDL-C of 30 mg/dl. It was inherited from the father who also showed TGs 232 and HDL-C 39 mg/dl. It is located in the amino-terminal domain of the protein that represents the site with the catalytic activity and it is also close to a glycosylation site critical for the proper maturation of the protein. Furthermore, the *in silico* analysis indicated that it could be probably damaging (PolyPhen-2 score = 0.099; Panther,  $P_{deleterious}$  = 0.221). Taking together, these results highlight that p.Ser45Asn might have a functional effect.

When the individual frequencies of *LPL* variants were compared between groups, we noticed that the p.N291S variant allele was significantly more common in AD than in control children (0.045 vs. 0.006;  $p = 0.010$ ) while, at the opposite, the p.S447\* allele tended to be more

**Table 3. Prevalence in the cohort of probands with atherogenic dyslipidemia of non-synonymous exonic variants in the LPL gene.**

Position	Variant name			Allele frequencies		Comparison in respect to controls without AD			Comparison in respect to other databases			
	DNA level	Protein level <sup>a</sup>	SNP identifier	Probands with AD	Controls without AD	Other databases	P value	Odds ratio	95% confidence interval	P value	Odds ratio	95% confidence interval
Exon 2	c.106 G>A	p.Asp9Asn	rs1801177	A = 0.009 (n = 1/110)	A = 0.020 (n = 7/348)	A = 0.013 <sup>b</sup> (n = 10/758)	P = 0.686 <sup>d</sup>	0.447	0.054 to 3.675	P = 1.000 <sup>d</sup>	0.686	0.087 to 5.416
Exon 2	c.215 G>A	p. Ser45Asn	new <sup>#</sup>	A = 0.009 (n = 1/110)	A = 0 (n = 0/348)	—	P = 0.240 <sup>d</sup>	9.548	0.386 to 236.3	—	—	—
Exon 6	c.953 A>G	p. Asn291Ser	rs268	G = 0.045 (n = 5/110)	G = 0.006 (n = 2/348)	G = 0.016 <sup>b</sup> (n = 12/758)	*P = 0.010 <sup>d</sup>	8.238	1.575 to 43.10	P = 0.053 <sup>d</sup>	2.960	1.022 to 8.573
Exon 8	c.1174 C>G	p. Leu365Val	rs118204078	G = 0.009 (n = 1/110)	G = 0 (n = 0/348)	G = 0.0001 <sup>c</sup> (n = 1/8600)	P = 0.240 <sup>d</sup>	9.548	0.386 to 236.3	*P < 0.0001 <sup>e</sup>	78.89	4.899 to 1270
Exon 9	c.1421 C>G	p.S447*	rs328	G = 0.064 (n = 7/110)	G = 0.126 (n = 44/348)	G = 0.123 <sup>b</sup> (n = 93/758)	P = 0.082 <sup>d</sup>	0.470	0.205 to 1.075	P = 0.078 <sup>d</sup>	0.486	0.219 to 1.077

<sup>a</sup>The name at protein level is without the pro-peptide.

n = number of variant alleles / number of total alleles

<sup>b</sup>Frequency from database 1000 genomes EUR;

<sup>c</sup>Frequency from ESP6500:European\_American, the only available for L365V SNP.

Depending on the sample size and absolute frequencies in the contingency table:

<sup>d</sup>Fisher exact test or

<sup>e</sup> $\chi^2$  was applied.

<sup>#</sup> = annotations for the new variant are: NC\_000008.11:g.19948306G>A; NG\_008855.1:g.14236G>A; NM\_000237.2:c.215G>A; NP\_000228.1:p.Ser45Asn

\* = statistically significant at indicated P level.

doi:10.1371/journal.pone.0120099.t003



prevalent in controls than in AD children (respectively 0.126 vs. 0.064,  $p = 0.082$ ). The difference in the prevalence of the other *LPL* variant alleles did not reach the statistical significance.

As the p.Asp9Asn, p.Asn291Ser and p.Leu365Val variants have been already demonstrated causing loss-of-function (LOF) alleles [28] and the novel p.Ser45Asn was classified as probably LOF, their cumulative prevalence was compared between AD and controls. We found that *LPL* LOF alleles were significantly more frequent in AD than in control children (0.073 vs. 0.026, respectively;  $p = 0.038$ ) determining for AD children an almost 3 times higher risk of being carriers of any of them (HR = 2.95; 95% CI 1.11–7.86;  $p = 0.038$ ). As the p.S447\* is a gain-of-function *LPL* variant associated with low TG levels [29], we performed a further analysis classifying *LPL* alleles in 3 classes (with the p.S447X, with all LOF and with wild type). A statistically significant difference of their distribution between AD and control children was evidenced ( $\chi^2 = 7.931$ ,  $p = 0.019$ ).

The comparison of lipid profile between AD children with ( $n = 8$ ) and without ( $n = 40$ ) LOF alleles in the *LPL* demonstrated that carriers had higher TG levels compared to non-carriers ( $175 \pm 96$  mg/dl vs.  $153 \pm 86$  mg/dl, respectively), even though the difference was not statistically significant probably due to the small sample size.

## Discussion

In this study, we sought to evaluate the metabolic and the genetic features of paediatric AD. Within a large cohort of children referred to a tertiary paediatric lipid clinic we found that about 15% of them showed a lipid phenotype classifiable as AD. Although this figure cannot be considered representative of the prevalence of AD in the general population of children, it suggests that AD is a rather frequent lipid abnormality among children with dyslipidaemia, certainly more common than dominant hypercholesterolemia (7.9%) and just lower than that of isolated hypertriglyceridemia (17.0%). We have classified AD based upon arbitrary age- and sex- specific lipoproteins cut-off values, and some have raised concern about the reliability of this criterion for classifying dyslipidemia in children [30]. Nevertheless, we found that AD children showed a constellation of several metabolic abnormalities such as greater waist circumference, higher fasting levels of plasma glucose and insulin and reduced insulin sensitivity, higher levels of hs-CRP and lower levels of adiponectin. It is also noteworthy that, compared to controls, AD children showed an abnormal composition of LDL fraction as suggested by the increased LDL-C/ApoB ratio. All these abnormalities have been already reported in adults diagnosed with AD [3, 8], thus suggesting that they may represent early events in the development of the AD trait. In addition, this finding indicates that the AD classification we used identified a group of children showing an array of generalized metabolic disorders.

It has been reported in adulthood that AD is a component of MetS [31]. This seems to be partially true in childhood as we observed that only about 40% of AD children showed features of MetS. This latter finding is consistent with previous observations indicating that at younger ages (<35 years) AD is a less robust identifier of MetS, but may reflect the predisposition to an isolated lipid disorder [32]. It must be, however, recognized that we cannot exclude that AD in many children might foreshadow the development of MetS later in life. Moreover, AD has been reported to be strongly related with obesity [4]. However, it must be noted that the multiple metabolic abnormalities in AD children, although associated with increased waist circumference, developed in the context of borderline-normal body fat and persisted even after adjustment for measures of adiposity. One possible interpretation of our data is that the underlying metabolic defects in AD children reflect an insulin-resistant state that extends beyond adipose tissue. Indeed, previous investigators have postulated a condition in which a primary condition of insulin resistance is responsible for multiple metabolic disorders, including

dyslipidemia [33]. In addition, the observation that parents and siblings of AD children showed predominantly abnormal lipid concentrations (and to a lesser extent visceral obesity and insulin resistance) might also argue in favour for the co-existence of inherited defects in apoB-containing lipoproteins metabolism in AD [34]. Indeed, it would be not surprising that an insulin resistant state on a background of genetic susceptibility to metabolic abnormalities worsens the expression of dyslipidemia.

An important finding of our study was that several traits associated to AD showed high degree of heritability. Our results are in line with previous studies that provided evidence for a strong association between parental metabolic disorders and abdominal obesity, high triglycerides and low HDL-C in their offspring [35]. Interestingly, in our AD families, beside plasma glucose, non-HDL-C and apoB presented the highest levels of heritability thus arguing in favor for the existence of an inherited defect in apoB-containing lipoproteins metabolism in AD children. It must be noted, however, that our children shared the same family environment or behaviour and this may emphasize the role of inheritance. Nonetheless, our data strongly argue in favour of a significant genetic component in AD.

In this study, we have also investigated the role of *LPL* and *APOAI* as candidate genes in predisposing children to develop AD. No sequence changes were found in *APOAI*, but 14.5% of AD probands presented variants in *LPL* gene. AD children as a group showed 3 times higher frequency of heterozygous LOF mutations in this gene. Moreover, the presence of *LPL* LOF variants appeared to be able to affect the hypertriglyceridemic trait in affected children. Based on these results we could postulate that abnormality in *LPL*, even though not causative, might favour the development (or the worsening) of the hypertriglyceridemic trait in, at least, a subset of AD children. It is well known that mild-to-moderate hypertriglyceridemia as well as lower HDL-C are typically multigenic [36] and therefore other genes might be responsible of susceptibility to the AD phenotype in the youth. Further resequencing studies in larger cohorts of AD children will be necessary to shedding more light on these aspects.

## Conclusions

Our study demonstrated that AD is a common dyslipidemia in childhood and this definition, although based on rather arbitrary cut-off criteria, identified a group of children showing several underlying metabolic abnormalities, many of which appear to be under a genetic influence. In particular, our data might suggest that the interaction between abnormalities in insulin sensitivity and in the metabolism of apoB-containing lipoprotein could represent early events in AD, which might later associate with unfavorable changes in visceral fat deposition. Moreover, some dyslipidemic children also carry abnormalities in the *LPL* activity, which may also give contribution to a hypertriglyceridemic component of AD. Overall these findings, not only confirm the complex nature of AD, but also have practical clinical implications. In fact, they strongly suggest that an early detection of children with AD would allow the identification of individuals highly prone to develop cardiometabolic risk factors in adulthood and therefore would most benefit of earlier preventive interventions.

## Supporting Information

**S1 File. Supplementary Methods.**  
(PDF)

**S1 Table. Primers for PCR amplification and cycle sequencing of *APOAI* and *LPL* genes.**  
(PDF)

**S2 Table. Primers for minisequencing of *LPL* gene.** The underlined nucleotides are the mobility tail added.

(PDF)

**S3 Table. Correlations between variables in the whole group of study children (n = 283).**

(PDF)

**S4 Table. Heritability ( $h^2$ ) values and effect of covariates (age, sex and their interaction) in the whole sample and stratified for case/control families.**

(PDF)

## Acknowledgments

We wish to thank Dr. Bruno Mazzarella and Renzo Cantini and Pierpaolo Spanedda for the technical support in the laboratory measurements. The authors are grateful to the children and their parents for the participation into the study.

## Author Contributions

Conceived and designed the experiments: MA AM FM ML. Performed the experiments: AM GT FC GF EC MM FG LI RS. Analyzed the data: AM MA. Contributed reagents/materials/analysis tools: RS ML FC. Wrote the paper: AM GT ML MA.

## References

1. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. *Med Clin North Am.* 2004; 88:897–909 PMID: [15308384](#)
2. Krauss RM, Siri PW. Metabolic abnormalities: triglyceride and low-density lipoprotein. *Endocrinol Metab Clin North Am.* 2004; 33:405–415 PMID: [15158526](#)
3. Grundy SM. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. *Circulation.* 1997; 95:1–4 PMID: [8994405](#)
4. Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. *Expert Opin Pharmacother.* 2011; 12:13–30. doi: [10.1517/14656566.2010.502529](#) PMID: [20629587](#)
5. Brian W. Hyperlipidemia in children. *Tromb Res.* 2006; 118: 49–58 PMID: [16709475](#)
6. Magnussen CG, Venn A, Thomson R, Juonala M, Srinivasan SR, Viikari JS, et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. *J Am Coll Cardiol.* 2009; 10: 860–869 doi: [10.1016/j.jacc.2008.09.061](#) PMID: [19264243](#)
7. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. *Clin Chem.* 2006; 52: 853–859. PMID: [16556684](#)
8. Barter P, McPherson YR, Song K, Kesäniemi YA, Mahley R, Waeber G et al. Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. *J Clin Endocrinol Metab.* 2007; 92: 2041–5. PMID: [17389699](#)
9. Feng Y, Zang T, Xu X, Xu X. Familial aggregation of metabolic syndrome and its components in a large Chinese population. *Obesity.* 2008; 16:125–129. doi: [10.1038/oby.2007.22](#) PMID: [18223624](#)
10. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. *J Lipid Res.* 1996; 37:693–707 PMID: [8732771](#)
11. Kusunoki M, Tsutsumi K, Sato D, Nakamura A, Habu S, Mori Y, et al. Activation of lipoprotein lipase increases serum high density lipoprotein 2 cholesterol and enlarges high density lipoprotein 2 particles in rats. *Eur J Pharmacol.* 2011; 668: 337–339 doi: [10.1016/j.ejphar.2011.06.040](#) PMID: [21756896](#)
12. Miller M, Zhan M. Genetic determinants of low high-density lipoprotein cholesterol. *Curr Opin Cardiol.* 2004; 19:380–384 PMID: [15218400](#)

13. Campagna F, Martino F, Bifulco M, Montali A, Martino E, Morrone F et al. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. *Atherosclerosis*. 2008; 196:356–364 PMID: [17196209](#)
14. Goodman E, Daniels SR, Meigs JB, Dolan LM. Instability in the diagnosis of metabolic syndrome in adolescents. *Circulation*. 2007; 115: 2316–2322 PMID: [17420347](#)
15. Martino F, Puddu PE, Pannarale G, Colantoni C, Zannoni C, Martino E et al. Arterial blood pressure and serum lipids in a population of children and adolescents from Southern Italy: the Calabrian Sierras Community Study (CSCS). *Int J Cardiol*. 2013; 168:1108–1114. doi: [10.1016/j.ijcard.2012.11.045](#) PMID: [23201079](#)
16. Menotti A, Seccareccia F, Lanti MD. RIFLE Project Research Group. Mean levels and distribution of some cardiovascular risk factors in Italy in the 1970's and 1980's: the Italian RIFLE Pooling Project: risk factors and life expectancy. *G Ital Cardiol*. 1995; 25: 1539–1572 PMID: [8707004](#)
17. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004; 109: 433–438. PMID: [14744958](#)
18. Fernández JR, Redden DT, Pietrobello A, Allison DB. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. *J Pediatr*. 2004; 145:439–444 PMID: [15480363](#)
19. Menghetti E, Virdis R, Strambi M, Patriarca V, Riccioni MA, Fossali E et al. Blood pressure in childhood and adolescence: the Italian normal standards. Study Group on Hypertension' of the Italian Society of Pediatrics. *J Hypertens*. 1999; 17:1363–1372 PMID: [10526895](#)
20. Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. *Arterioscler Thromb Vasc Biol*. 2013; 33:1706–1713 doi: [10.1161/ATVBAHA.113.301397](#) PMID: [23661675](#)
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: IR and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985; 28: 412–419. PMID: [3899825](#)
22. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988; 16:1215. PMID: [3344216](#)
23. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet*. 1998; 62:1198–1211 PMID: [9545414](#)
24. Wägner AM, Jorba O, Rigla M, Alonso E, Ordóñez-Llanos J, Pérez A. LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. *Acta Diabetol*. 2002; 39:215–220. PMID: [12486496](#)
25. Fisher RM, Humphries SE, Talmud PJ. Common variations in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. *Atherosclerosis*. 1997; 135: 145–149. PMID: [9430364](#)
26. Reymer PW, Groenemeyer BE, Gagné E, Miao L, Appelman EE, Seidel JC et al. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. *Hum Mol Genet*. 1995; 4:1543–1549 PMID: [8541837](#)
27. De Bruin TW, Mailly F, Van Berlingen HH, Fisher R, Castro Cabezas M. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidemia. *Eur J Clin Invest*. 1996; 26:631–639 PMID: [8872057](#)
28. Clivar database: Available from <http://www.clinvar.com>. Accessed 10 February 2014)
29. Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJ et al. Lipoprotein Lipase S447X A Naturally Occurring Gain-of-Function Mutation. *Arterioscler Thromb Vasc Biol*. 2006; 26:1236–1245 PMID: [16574898](#)
30. Magnussen CG, Raitakari OT, Thomson R, Juonala M, Patel DA, Viikari JS et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study *Circulation*. 2008; 117:32–42
31. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. *Clin Cornerstone*. 2006; 8 (Suppl 1): S21–27 PMID: [16903166](#)
32. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesäniemi YA, Mahley RW et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). *Am J Cardiol*. 2005; 95:194–198 PMID: [15642551](#)
33. Reaven GM. The metabolic syndrome: is this diagnosis necessary? *Am J Clin Nutr*. 2006; 83:1237–1247 PMID: [16762930](#)

34. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. *Diabetes* 2003; 52:803–811. PMID: [12606523](#)
35. Lee KE, Klein BE, Klein R. Familial aggregation of components of the multiple metabolic syndrome in the Framingham Heart and Offspring Cohorts: Genetic Analysis Workshop Problem 1. *BMC Genet.* 2003; 4 (Suppl 1):S94 PMID: [14975162](#)
36. Yu Y, Wyszynski DF, Waterworth DM, Wilton SD, Barter PJ, Kesäniemi YA, et al. Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. *J Lipid Res.* 2005; 46:2202–2213. PMID: [16061952](#)

## Supplementary Methods

### Genetic Analysis

The promoter and all 4 exons and introns of APOA1 gene and the promoter and the 10 exons (with adjacent intronic regions) of LPL gene were analyzed. In particular, the APOA1 gene was divided into 4 zones for the PCR amplification (**S2 Table A**); each zone was subsequently divided into two parts for sequencing (**S2 Table B**). For the LPL gene, the primers flanking the exons were used for both PCR amplification and sequencing (**S2 Table C**). PCR amplifications were performed in a total volume of 15 µl with 50 ng of genomic DNA, 6 pmols of each primer, 0.25 units of Go Taq hot start polymerase (Promega, USA), 175 µM of each dNTP (Fermentas, USA), 1.5 mM MgCl<sub>2</sub> and 1x manufacturer's buffer. The PCR cycle was the following: 2' 95°C; 35 cycles of 45'' 94°C, 1' 30'' 58°C, 2'30'' 72°C followed by 7' 72°C. PCR products were purified by a common protocol based on thermosensitive alkaline phosphatase (Fermentas, USA) and exonuclease I (USB Corporation, USA). Sequencing reactions were performed by using the Big Dye Terminator Reaction Kit version 1.1 (Applied Biosystems, USA) according to the manufacturer's instructions by using the genetic analyzer ABI PRISM 3130xl (Applied Biosystems, USA). Sequencing products were purified by Montage SEQ96 sequencing reaction cleanup kit (Millipore, USA) following manufacturer instructions and subsequently analyzed by the genetic analyzer. The sequence data were analyzed by using the software SeqScape (Applied Biosystems, USA) personalized for the semi-automatic recognition of sequence variations possibly found in the studied zones.

The SNPs identified in the LPL gene were investigated in the general population by the SNaPshot assay (Life technologies, USA). Briefly, the method consisted in the amplification of regions containing SNPs by a multiplex PCR of 5'-UTR and exons 2, 6, 8 and 9 of LPL gene (**S2 Table C**) that was subsequently purified by the exonuclease I – alkaline phosphatase method. Purified PCR products underwent extension reactions by using the primers reported in the **S3 Table** and in the presence of fluorescent ddNTPs. The polymerase extends the primer by only one nucleotide, adding a single ddNTP at its 3' end. After alkaline phosphatase purification, extension products were analyzed by the genetic analyzer. The data analysis was performed by a personalized template for Genotyper software (Applied Biosystems, USA).



**S2 Table.** Primers for PCR amplification and cycle sequencing of *APOA1* and *LPL* genes.**A) Primers for PCR amplification of APOA1.**

ANALYZED ZONE	FORWARD	REVERSE	PRODUCT SIZE (bp)	Ta (°C)
5' UTR - exon 3	5'-TCCTCTGCCAACACAATGG-3'	5'-GGCCAGGTCCTTCACTCG-3'	878	58
Exon 2 – exon 4	5'-TCCTGACGGGTAGGTGTCC-3'	5'-GCTGTCCCAGTTGTCAAGG-3'	970	58
Intron 3 - 3' UTR (up)	5'-CCAGCTCTGTCTCCTTTTAGC-3'	5'-GCACGGAGTTGTTGAGATCC-3'	981	58
Exon 4 - 3' UTR (down)	5'-GAGCTTCAAGGTCAGCTTCC-3'	5'-TCCTGGCCTGAAGTGATACG-3'	1151	58

**B) Primers for cycle sequencing of APOA1.**

ApoA1	FORWARD	REVERSE	PRODUCT SIZE (bp)	Ta (°C)
5' UTR (up) – intron 1	5'-CTCCCATGGAGGGGAAGG-3'	5'-CACAGAGCGGGAGAAGACC-3'	421	58
5' UTR (down) – intron 2 (down)	5'-TGGCTGCAGACATAAATAGGC-3'	5'-CTGAGATCTGAGCCGAAAGG-3'	465	58
Intron 2 (up) – intron 3 (up 1)	5'-CCTAACCTAGGGAGCCAACC-3'	5'-GCCCAGCTCATCAGATATTAGG-3'	441	58
Exon 3 – intron 3 (down)	5'-GCGGCAGAGACTATGTGTCC-3'	5'-GCAGTGGCCTAGCATTTC-3'	554	58
Intron 3 (up 2) – exon 4 (down)	5'-CCTTTTAGCTCCTCTCTGTGC-3'	5'-AGCTCGTGCAGCTTCTGG-3'	476	58
Exon 4 (up) – 3' UTR (up)	5'-AGCTCTACCGCCAGAAGG-3'	5'-AAGCTGCTTCCCACTTTGG-3'	459	58
Exon 4 (down) – 3' UTR (down)	5'-AAGCTCAACACCCAGTGAGG-3'	5'-TAGTGGGAGGGGGATACTGG-3'	657	58
3' UTR (distal)	5'-GAAGCGCTTGGAGTTTGC-3'	5'-TGATACGCCCACCTCAGC-3'	537	58

**C) Primers for PCR amplification and cycle sequencing of LPL.**

ANALYZED ZONE	FORWARD	REVERSE	PRODUCT SIZE (bp)	Ta (°C)
5' UTR	5'-CGTGAATCGATGTAAACCTGTG-3'	5'-GTTTGGCGCTGAGCAAGT-3'	377	58
Exon 1 and adjacent intronic zones	5'-CAGTCACATAAGCAGCCTT-3'	5'-TTCCAACCTCCTTCTTCTC-3'	401	58
Exon 2 and adjacent intronic zones	5'-CGTTGGAGCATCTGTTGTTCT-3'	5'-ATGTGGGGTGCGGACCCATC-3'	427	58
Exon 3 and adjacent intronic zones	5'-TTGGGCTGATGTATCTATGAC-3'	5'-GGCAGGACTATTTATTGGC-3'	451	58
Exon 4 and adjacent intronic zones	5'-ATTTTTGGCAGAACTGTAAGCAC-3'	5'-AAATCTGCAGGCATTGTGTG-3'	408	58
Exon 5 and adjacent intronic zones	5'-TCATTTTAGAAGGAGCCAAG-3'	5'-GTGGTCATGCTGAACATTG-3'	569	58
Exon 6 and adjacent intronic zones	5'-ACTCTCTTGAAGGTGGGTGG-3'	5'-ATGGGAATTAGAAGCCTCAGAC-3'	624	58
Exon 7 and adjacent intronic zones	5'-TTCCATGTGTGTGCACTTCC-3'	5'-CTTGTTTCTAGGCATCGCTCT-3'	350	58
Exon 8 and adjacent intronic zones	5'-GCAGGGAGAGCTGATCTCTATAA-3'	5'-TGTGAAGGCCCTGAAATAC-3'	318	58
Exon 9 and adjacent intronic zones	5'-CCCTCTGATTCTGATGTGGC-3'	5'-CTGGTGATGGGGTGAAGAG-3'	363	58
Exon 10 and intron 9 adjacent intronic zone - 3' UTR	5'-GTCTTCCATTCTACAAACCTG-3'	5'-TTTTACTCTGCGCTCAAACAAT-3'	497	58

**S3 Table** . Primers for minisequencing in the LPL gene. The underlined nucleotides are the mobility tail added.

VARIATION	PRIMER
p.Asp9Asn	5'- <u>GGAAAAGAGAAAGGAAAAAAAA</u> TTCCAGAAAGAAGAGATTTTATC-3'
p.Ser45Asn	5'- <u>AAAAAA</u> CTACCTGTCATTTCAATCACA-3'
p.Asn291Ser	5'-AATCTGGGCTATGAGATCA-3'
p.Leu365Val	5'- <u>AAAGGAAAACACAAATAAGACCTACTCCTTC</u> -3'
p.Ser447*	5'- <u>AGAAAAAAGGGAAAA</u> ATGACAAGTCTCTGAATAAGAAGT-3'

**S4 Table. Correlations between variables in the whole group of study children (n=283)**

<b>Variables</b>	<b>Age</b>	<b>TC</b>	<b>HDL-C</b>	<b>TG</b>	<b>LDL-C</b>	<b>FBG</b>	<b>Insulin</b>	<b>hs-CRP</b>	<b>Apo B</b>	<b>Apo A1</b>	<b>Adiponectin</b>	<b>HOMA-IR</b>	<b>BMI</b>
<b>TC</b>	0.025												
<b>HDL-C</b>	-0.006	0.224**											
<b>TG</b>	0.070	0.008	-0.532**										
<b>LDL-C</b>	0.009	0.944**	-0.013	-0.096									
<b>FBG</b>	0.221**	0.010	-0.224**	0.300**	0.008								
<b>Insulin</b>	0.486**	-0.101	-0.312**	0.356**	-0.089	0.246**							
<b>hs-CRP</b>	-0.009	-0.082	-0.154*	0.007	-0.021	-0.055	0.160*						
<b>ApoB</b>	0.020	0.579**	-0.144*	-0.014	0.671**	0.046	0.016	0.040					
<b>Apo A1</b>	0.070	0.130*	0.589**	-0.267**	-0.024	-0.096	-0.166*	-0.138*	-0.042				
<b>Adiponectin</b>	-0.381**	0.141	0.224*	-0.142	0.093	-0.061	-0.353**	-0.113	0.023	0.054			
<b>HOMA-IR</b>	0.483**	-0.066	-0.332**	0.420**	-0.063	0.424**	0.970**	0.151*	0.043	-0.146*	-0.343**		
<b>BMI</b>	0.410**	-0.006	-0.275**	0.323**	0.010	0.340**	0.575**	0.043	0.076	-0.163*	-0.413**	0.587**	
<b>Waist circ.</b>	0.617**	-0.060	-0.373**	0.467**	-0.044	0.190	0.712**	0.151	0.066	-0.153	-0.319*	0.649**	0.841**

TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; LDL-C, low density lipoprotein cholesterol; FBG, fasting blood glucose; hs-CRP, high sensitivity C Reactive Protein; HOMA-IR, HOmeostasis Model Assessment of IR index; BMI, body mass index

\*p< 0.05; \*\*p< 0.01

**S5 Table.** Heritability (h2) values and effect of covariates (age, sex and their interaction) in the whole sample and stratified for case/control families.

	Overall (1052 subjects, 283 families)			AD families (229subjects, 62 families)			Control families (823subjects, 221families)		
	h2 (SE) (%)	P values	Covariates (%)	h2 (SE) (%)	P values	Covariates (%)	h2 (SE) (%)	P values	Covariates (%)
BMI	<b>44.1 (5.7)</b>	9.E-15	<b>53.7</b>	<b>52.1 (11.4)</b>	6.E-06	<b>33.5</b>	<b>40.8 (6.6)</b>	2.E-10	<b>57.9</b>
Waist circumference	<b>29.7 (9.9)</b>	1.E-03	<b>67.6</b>	<b>45.6 (17.8)</b>	6.E-03	<b>55.0</b>	<b>17.7 (11.9)</b>	0.06	<b>80.1</b>
Hip circumference	<b>42.2 (12.4)</b>	4.E-04	<b>0.2</b>	<b>78.9 (18.0)</b>	1.E-04	<b>60.6</b>	<b>22.4 (15.9)</b>	0.08	<b>0.0</b>
PAD	<b>15.8 (8.2)</b>	2.E-02	<b>24.4</b>	Ne	-		<b>22.5 (9.1)</b>	5.E-03	<b>24.4</b>
PAS	<b>18.1 (8.8)</b>	2.E-02	<b>30.1</b>	<b>5.3 (21.2)</b>	0.40	<b>28.5</b>	<b>20.4 (9.6)</b>	1.E-02	<b>30.9</b>
Glucose	<b>88.9 (3.7)</b>	4.E-59	<b>17.1</b>	<b>90.4 (7.8)</b>	8.E-15	<b>13.9</b>	<b>86.2 (4.4)</b>	1.E-42	<b>18.5</b>
Insulin	<b>22.1 (6.4)</b>	1.E-04	<b>2.6</b>	<b>26.9 (14.3)</b>	3.E-02	<b>0.2</b>	<b>18.9 (7.2)</b>	3.E-03	<b>6.4</b>
HOMA	<b>32.2 (6.8)</b>	5.E-07	<b>3.0</b>	<b>30.9 (15.8)</b>	2.E-02	<b>0.0</b>	<b>26.8 (7.7)</b>	2.E-04	<b>7.2</b>
Total cholesterol	<b>45.7 (6.1)</b>	7.E-14	<b>15.0</b>	<b>71.2 (10.8)</b>	2.E-08	<b>20.5</b>	<b>37.5 (7.1)</b>	3.E-08	<b>14.3</b>
HDL	<b>63.5 (4.6)</b>	1.E-35	<b>13.5</b>	<b>32.8 (13.5)</b>	5.E-03	<b>21.5</b>	<b>48.3 (6.1)</b>	5.E-15	<b>18.8</b>
Non-HDL	<b>55.2 (5.5)</b>	3.E-21	<b>12.7</b>	<b>68.6 (11.5)</b>	4.E-07	<b>8.7</b>	<b>48.7 (6.3)</b>	2.E-14	<b>14.9</b>
Non-HDL/HDL ratio	<b>66.2 (4.9)</b>	2.E-31	<b>22.3</b>	<b>47.4 (14.8)</b>	1.E-03	<b>10.7</b>	<b>55.0 (6.2)</b>	1.E-16	<b>29.4</b>
LDL	<b>58.9 (5.4)</b>	6.E-25	<b>8.4</b>	<b>74.6 (9.5)</b>	2.E-10	<b>8.8</b>	<b>52.5 (6.3)</b>	2.E-16	<b>8.8</b>
Tryglicerides	<b>58.4 (5.6)</b>	3.E-22	<b>27.3</b>	<b>28.7 (13.7)</b>	1.E-02	<b>5.9</b>	<b>45.0 (6.7)</b>	4.E-11	<b>28.2</b>
ApoAI	<b>67.0 (4.7)</b>	2.E-35	<b>8.1</b>	<b>51.4 (10.7)</b>	2.E-06	<b>12.5</b>	<b>66.4 (5.7)</b>	3.E-25	<b>8.3</b>
ApoB	<b>74.8 (4.8)</b>	6.E-36	<b>13.5</b>	<b>81.3 (9.9)</b>	8.E-10	<b>11.2</b>	<b>73.0 (5.4)</b>	9.E-29	<b>13.6</b>
ApoAI/HDL ratio	<b>72.2 (5.1)</b>	3.E-33	<b>13.5</b>	<b>57.8 (12.9)</b>	2.E-05	<b>12.2</b>	<b>64.7 (6.4)</b>	1.E-19	<b>19.3</b>
ApoB/non-HDL ratio	<b>83.0 (4.1)</b>	1.E-51	<b>0.0</b>	<b>77.3 (9.6)</b>	4.E-10	<b>0.2</b>	<b>84.5 (4.5)</b>	1.E-42	<b>0.7</b>
ApoB/Apo-aI ratio	<b>75.8 (4.8)</b>	6.E-38	<b>11.6</b>	<b>60.8 (11.5)</b>	1.E-06	<b>6.4</b>	<b>76.9 (5.3)</b>	2.E-31	<b>12.9</b>
Adiponectin	<b>16.8 (13.2)</b>	0.10	<b>15.5</b>	<b>7.6 (17.3)</b>	0.33	<b>7.2</b>	<b>43.8 (18.7)</b>	2.E-02	<b>22.0</b>
CRP	<b>23.4 (7.4)</b>	5.E-04	<b>8.4</b>	<b>20.7 (14.4)</b>	0.07	<b>0.0</b>	<b>25.2 (8.6)</b>	1.E-03	<b>14.8</b>
MetSyn	<b>65.5 (16.9)</b>	8.E-05	<b>1.82*</b>	Ne	-		<b>49.6 (147.2)</b>	0.40	<b>20.5*</b>

\*Kullback-Leibler R-squared for categorical variables

CORRECTION

# Correction: Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects

**Anna Montali, Gessica Truglio, Francesco Martino, Fabrizio Ceci, Giampiero Ferraguti, Ester Ciociola, Marianna Maranghi, Francesco Gianfagna, Licia Iacoviello, Roberto Strom, Marco Lucarelli, Marcello Arca**

There is an error in affiliation 5 for authors Francesco Gianfagna and Licia Iacoviello. Affiliation 5 should be: Department of Epidemiology and Prevention, Laboratory of Molecular and Nutritional Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy.

## Reference

1. Montali A, Truglio G, Martino F, Ceci F, Ferraguti G, Ciociola E, et al. (2015) Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects. PLoS ONE 10(4): e0120099. doi: [10.1371/journal.pone.0120099](https://doi.org/10.1371/journal.pone.0120099) PMID: [25897955](https://pubmed.ncbi.nlm.nih.gov/25897955/)



## OPEN ACCESS

**Citation:** Montali A, Truglio G, Martino F, Ceci F, Ferraguti G, Ciociola E, et al. (2015) Correction: Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects. PLoS ONE 10(7): e0133335. doi:10.1371/journal.pone.0133335

**Published:** July 15, 2015

**Copyright:** © 2015 Montali et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.